se of combined measurements of serum infliximab and anti-infliximab antibodies in the treatment of patients with Crohns disease failing infliximab therapy

Department of medical gastroenterology, Herlev Hospital0 个研究点开始时间: 2009年2月25日最近更新: 2016年8月8日

适应症

试验速览

暂无简介。

•1. Patient must be able to understand the information given to him/her and give written informed consent.
•2. Definitive diagnosis of Crohn’s disease (confirmed by recent radiological, endoscopic and/or histological evidence according to international criterias) .
•3. Minimum 18 years.
•4. Previous good response to at least 3 doses (5mg/kg) of infliximab (as judged by the treating physician).
•5. Loss of response to standard doses of infliximab (as judged by the treating physician).
•6. For patients with luminal disease, the CDAI should be above 220 points at inclusion.
•7. For patients with fistulising disease only, at least one draining perianal fistula (confirmed by radiography, MR, ultrasound or physical examination) should be present.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 4

•1. Any contraindication to continued infliximab treatment
•2. Short bowel syndrome
•3. Bowel resection within 12 weeks of inclusion.
•4. Current or recent history of severe, progressive, and/or uncontrolled renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease.
•5. Pregnancy
•6. History of alcohol or drug abuse within the prior year
•7. Patients who do not meet concomitant medication criteria
•8. Any other condition, which in the Investigator’s juegment would make the patient unsuitable for inclusion in the study.

发起方

Department of medical gastroenterology, Herlev Hospital